Cutaneous lupus erythematosus: an update on pathogenesis and future therapeutic directions
D Niebel, L de Vos, T Fetter, C Brägelmann… - American Journal of …, 2023 - Springer
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various
organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus …
organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus …
Deucravacitinib shows superior efficacy and safety in cutaneous lupus erythematosus compared to various biologics and small molecules–A systematic review and …
LA Bokor, K Martyin, M Krebs, NÁ Galajda… - Autoimmunity …, 2024 - Elsevier
Background Novel therapies for cutaneous lupus erythematosus (CLE) and systemic lupus
erythematosus (SLE) demonstrated efficacy and safety in previous trials. However, data on …
erythematosus (SLE) demonstrated efficacy and safety in previous trials. However, data on …
[HTML][HTML] Successful treatment of severe chronic cutaneous lupus with anifrolumab: A series of 6 cases
EH Kowalski, A Stolarczyk, CT Richardson - JAAD Case Reports, 2023 - Elsevier
Cutaneous lupus erythematosus (CLE) is a chronic autoimmune condition that
encompasses several subtypes with varying morphologies but a shared pathogenesis and …
encompasses several subtypes with varying morphologies but a shared pathogenesis and …
Anifrolumab in refractory systemic lupus erythematosus: a real-world, multicenter study
Objective To report real-world experience on the use of anifrolumab (ANI) in refractory
systemic lupus erythematosus (SLE). Methods The present study is a multicenter …
systemic lupus erythematosus (SLE). Methods The present study is a multicenter …
Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice
Y Tanaka - RMD open, 2023 - rmdopen.bmj.com
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease
characterised by unpredictable flares. Many patients with SLE are unable to achieve the …
characterised by unpredictable flares. Many patients with SLE are unable to achieve the …
[HTML][HTML] Clinical Trials of Interferon Inhibitors in Systemic Lupus Erythematosus and Preliminary Real-World Efficacy of Anifrolumab
S Díaz-Planellas, D Katsifis-Nezis… - Mediterranean …, 2024 - pmc.ncbi.nlm.nih.gov
Approval of anifrolumab for the treatment of moderate-to-severe systemic lupus
erythematosus (SLE) in 2021 marked the success of a long quest to target the interferon …
erythematosus (SLE) in 2021 marked the success of a long quest to target the interferon …
[[Translated article]] Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses
D Martín-Torregrosa, M Mansilla-Polo… - Actas dermo …, 2024 - Elsevier
Anifrolumab is an inhibitor of the type I interferon receptor subunit 1 (IFNAR1) recently
approved for the management of moderate-to-severe systemic lupus erythematosus (SLE) …
approved for the management of moderate-to-severe systemic lupus erythematosus (SLE) …
The SLE Conundrum: A Comprehensive Analysis of Pathogenesis, Recent Developments, and the Future of Therapeutic Interventions
U Sharma - Critical Reviews™ in Immunology, 2025 - dl.begellhouse.com
Systemic lupus erythematosus (SLE) is a complex autoimmune disorder with multifactorial
interactions among various susceptibility factors. Significant strides have been made in …
interactions among various susceptibility factors. Significant strides have been made in …
Anifrolumab for Moderate and Severe Muco-Cutaneous Lupus Erythematosus: A Monocentric Experience and Review of the Current Literature
Refractory cutaneous manifestations constitute a significant unmet need in patients with
cutaneous lupus (CLE), even in the setting of systemic lupus erythematosus (SLE) with …
cutaneous lupus (CLE), even in the setting of systemic lupus erythematosus (SLE) with …
Nano‐encapsulated anandamide reduces inflammatory cytokines in vitro and lesion severity in a murine model of cutaneous lupus erythematosus
ET McCormick, A Draganski, S Chalmers… - Experimental …, 2023 - Wiley Online Library
Cutaneous lupus erythematosus (CLE) is a heterogeneous autoimmune skin disease which
occurs independently and in conjunction with systemic lupus erythematosus. Drug …
occurs independently and in conjunction with systemic lupus erythematosus. Drug …